Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong · Delayed Price · Currency is HKD 1.010
-0.060 (-5.61%)
Jul 31, 2026, 3:43 PM HKT
HKG:1652 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 747 | 591 | 591 | 1,021 | 1,084 | 943 | |
Market Cap Growth | 180.56% | 0% | -42.05% | -5.86% | 14.94% | -73.09% |
Enterprise Value | 992 | 906 | 964 | 1,249 | 1,351 | 1,059 |
Last Close Price | 1.01 | 0.80 | 0.80 | 1.37 | 1.43 | 1.23 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 46.17 |
PS Ratio | 2.45 | 1.94 | 1.71 | 1.64 | 1.95 | 1.99 |
PB Ratio | 1.87 | 1.49 | 1.51 | 1.65 | 1.57 | 1.17 |
P/TBV Ratio | 2.03 | 1.61 | 1.63 | 1.71 | 1.56 | 1.17 |
P/FCF Ratio | 9.34 | 7.40 | 7.64 | - | 11.07 | - |
P/OCF Ratio | 5.36 | 4.25 | 4.16 | - | 8.68 | 16.09 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.26 | 2.98 | 2.78 | 2.01 | 2.43 | 2.24 |
EV/EBITDA Ratio | 19.89 | 34.92 | - | 22.89 | 16.52 | 10.35 |
EV/EBIT Ratio | 167.26 | - | - | 52.87 | 26.31 | 13.09 |
EV/FCF Ratio | 12.42 | 11.34 | 12.45 | - | 13.79 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.85 | 0.85 | 1.05 | 0.62 | 0.38 | 0.38 |
Debt / EBITDA Ratio | 10.07 | 10.07 | - | 6.09 | 2.93 | 2.79 |
Debt / FCF Ratio | 4.26 | 4.26 | 5.34 | - | 2.69 | - |
Net Debt / Equity Ratio | 0.62 | 0.62 | 1.00 | 0.56 | 0.17 | 0.26 |
Net Debt / EBITDA Ratio | 9.52 | 9.52 | -11.29 | 6.33 | 1.45 | 2.02 |
Net Debt / FCF Ratio | 3.09 | 3.09 | 5.05 | -3.63 | 1.21 | -2.70 |
Asset Turnover | 0.22 | 0.22 | 0.25 | 0.42 | 0.38 | 0.31 |
Inventory Turnover | 0.89 | 0.89 | 0.91 | 1.73 | 2.11 | 1.48 |
Quick Ratio | 0.33 | 0.33 | 0.33 | 0.50 | 0.61 | 0.70 |
Current Ratio | 0.56 | 0.56 | 0.59 | 0.85 | 0.85 | 1.04 |
Return on Equity (ROE) | -3.25% | -3.25% | -40.58% | -6.18% | -5.46% | 2.53% |
Return on Assets (ROA) | -0.46% | -0.46% | -3.25% | 1.00% | 2.19% | 3.32% |
Return on Invested Capital (ROIC) | -1.57% | -1.39% | -8.34% | 2.69% | 5.88% | 6.72% |
Return on Capital Employed (ROCE) | -2.40% | -2.40% | -14.50% | 3.20% | 7.20% | 8.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.76% | -2.22% | -33.97% | -3.92% | -3.61% | 2.17% |
FCF Yield | 10.70% | 13.51% | 13.09% | -9.33% | 9.03% | -8.12% |
Dividend Yield | - | - | - | - | - | 0.91% |
Payout Ratio | - | - | - | - | - | 49.90% |
Buyback Yield / Dilution | 0.09% | 0.09% | 1.60% | 0.53% | 1.85% | 2.51% |
Total Shareholder Return | 0.09% | 0.09% | 1.60% | 0.53% | 1.85% | 3.42% |